<DOC>
	<DOCNO>NCT00712348</DOCNO>
	<brief_summary>This multi-center , open-label , switchover trial ass safety taliglucerase alfa 30 patient Gaucher disease currently treat imiglucerase ( Cerezyme® ) enzyme replacement therapy .</brief_summary>
	<brief_title>Switchover Trial From Imiglucerase Plant Cell Expressed Recombinant Human Glucocerebrosidase</brief_title>
	<detailed_description>This multi-center , open-label , switchover trial ass safety taliglucerase alfa 30 patient Gaucher disease currently treat imiglucerase ( Cerezyme® ) ERT . Eligible patient enter 12-week Stability Evaluation Period establish stability disease . Patients stable disease switch imiglucerase treatment receive intravenous ( IV ) infusion taliglucerase alfa every two week total 20 IV infusion . The dose taliglucerase alfa equal patient 's previous imiglucerase dose . The infusion administer select investigational site ( clinic/hospital ) , infusion center , home . At end 9-month treatment period ( 20 visit , 38 week ) eligible patient offer enrollment open-label extension study .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Males female , 2 year old Confirmed diagnosis Gaucher disease enzymatic activity assay Stable Gaucher disease Treatment imiglucerase ( Cerezyme® ) least 2 year stable maintenance regimen ( dose regimen unchanged , except situation drug shortage ) least last six month Able provide write informed consent Currently take another experimental drug condition History allergy carrot History allergy beta lactam antibiotic Previous infusion reaction suspect allergic nature Cerezyme® Ceredase® receive premedication prevent infusion reaction Presence HIV and/or HBsAg and/or hepatitis C infection Presence unresolved anemia due iron , folic acid vitamin B12 deficiency Presence significant comorbidity could confound interpretation clinical response taliglucerase alfa Presence medical , emotional , behavioral psychological condition judgment Investigator would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Gaucher disease</keyword>
	<keyword>imiglucerase</keyword>
	<keyword>glucocerebrosidase</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>lysosomal storage disorder</keyword>
</DOC>